...
首页> 外文期刊>Current stem cell research & therapy >Mesenchymal Stem Cell Therapy for Inflammatory Bowel Diseases: Promise and Challenge
【24h】

Mesenchymal Stem Cell Therapy for Inflammatory Bowel Diseases: Promise and Challenge

机译:间充质干细胞治疗炎症性肠病:承诺和挑战。

获取原文
获取原文并翻译 | 示例
           

摘要

Inflammatory Bowel Disease (IBD) is a complicated disease that arises as a consequence of the interaction among environment, genetic factors and autoimmunity. Available therapeutic interventions with pharmacological or biological drugs have a very selective action. Mesenchymal stem cells (MSCs) have been emerging as a promising cellular therapy for the treatment of IBD due to their multifaceted functions. This article summarizes recent progress in both preclinical studies and clinical trials employing MSCs in IBD treatment. We justify the use of MSC-based cell therapy as a novel strategy for IBD, discuss the biological roles that MSCs play underlying their therapeutic effects focusing on their immune-suppressive effects, illustrate methods to improve MSCs for better repair, and pinpoint the obstacles hindering their success and the challenges to overcome before their ultimate application.
机译:炎症性肠病(IBD)是一种复杂的疾病,是环境,遗传因素和自身免疫之间相互作用的结果。可用药理或生物药物进行的治疗性干预措施具有非常高的选择性。间充质干细胞(MSCs)由于其多方面的功能已经成为一种有前途的细胞疗法,用于治疗IBD。本文总结了在IBD治疗中采用MSC的临床前研究和临床试验的最新进展。我们证明使用基于MSC的细胞疗法作为IBD的一种新策略是合理的,讨论了MSC发挥其生物学治疗作用的生物学作用(着重于其免疫抑制作用),阐明了改善MSC的方法以进行更好的修复,并指出了阻碍其发展的障碍它们的成功以及最终应用之前要克服的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号